With high throughput, we can tackle uveitis together on our path to preventing blindness. Our EAU model immunizes with IRBP and CFA and our EIU model using a lipopolysaccharide inject intravitreally, which avoids systemic effects.
EIU also includes cytokine and chemokine analysis using ELISA. Both EAU and EIU include histopathology conducted in-house and with a board-certified pathologist.
Anterior Segment Imaging
Using the MICRON ® IV, anterior segments capture progression of disease and provides in-life disease scoring.
Microinfusion Injection Delivery
Confirmation fundus images of each injection procedure that ensures proper delivery of treatment.
Topical Drug Delivery
Our staff is the most proficient and accurate staff to delivery treatments topically.
Available Uveitis Models
Experimental Autoimmune Uveitis in Lewis Rats
Our efficacy model utilizes immunization with IRBP+CFA for disease induction with a validated positive control. Animals undergo in-life clinical assessments in order to grade disease progression. Upon conclusion of the study whole eyes are assessed with H&E staining for a direct comparison against the clinical grades for validity. Additionally, aqueous humor and/or vitreous humor can be collected for inflammatory marker analysis.
Endotoxin-induced Uveitis in Lewis Rats
Our unique model delivers LPS by IVT injections unlike other models that use systemic approaches. This refined approach not only puts forward better results but also avoids unintended adverse effects seen from systemic injections. Like EAU, whole eyes are collected for H&E analysis to compare against the in-life clinical scores, and aqueous humor and vitreous humor can be collected for inflammatory marker analysis.
Results From Uveitis Models
By utilizing the MICRON ® IV for anterior segment imaging, we can grade in-life
We’re focused on providing you the best results possible and that includes taking advances model development
All capabilities in-house
This graph shows the ability of IRBP+CFA to induce uveitis and FTY-720 suppressing the inflammatory response
Here we show that delivery of LPS is just as effective at disease induction as systemic foot-pad injections.